Systems pharmacology of adverse event mitigation by drug combinations
about
Systems Medicine: The Application of Systems Biology Approaches for Modern Medical Research and Drug DevelopmentThe need for novel informatics tools for integrating and planning research in molecular and cellular cognitionKnowledge retrieval from PubMed abstracts and electronic medical records with the Multiple Sclerosis OntologyCo-prescription trends in a large cohort of subjects predict substantial drug-drug interactionsNovel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of AssaysHarnessing Big Data for Systems PharmacologyPrevention of antipsychotic-induced hyperglycaemia by vitamin D: a data mining prediction followed by experimental exploration of the molecular mechanism.Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data.Data-Driven Prediction of Beneficial Drug Combinations in Spontaneous Reporting Systems.Translational learning from clinical studies predicts drug pharmacokinetics across patient populations.DCDB 2.0: a major update of the drug combination database.A community computational challenge to predict the activity of pairs of compoundsSystems medicine: evolution of systems biology from bench to bedsideSystems Pharmacology Links GPCRs with Retinal Degenerative Disorders.Systems biology approaches for identifying adverse drug reactions and elucidating their underlying biological mechanisms.Synergistically acting agonists and antagonists of G protein-coupled receptors prevent photoreceptor cell degeneration.Characterizing the pocketome of Mycobacterium tuberculosis and application in rationalizing polypharmacological target selection.Signaling networks in MS: a systems-based approach to developing new pharmacological therapies.Topology, dynamics, and heterogeneity in immune signaling.Complex diseases require complex therapiesCombine and conquer: challenges for targeted therapy combinations in early phase trials.Pharmaceutical cocrystals: walking the talk.Mechanistic micro-structural theory of soft tissues growth and remodeling: tissues with unidirectional fibers.Is systems pharmacology ready to impact upon therapy development? A study on the cholesterol biosynthesis pathway.Systems biology: unlocking the complexities of disease to enhance medicine.Therapy: One plus one equals zero--drug combinations mitigate adverse effects.MSBIS: A Multi-Step Biomedical Informatics Screening Approach for Identifying Medications that Mitigate the Risks of Metoclopramide-Induced Tardive Dyskinesia.Evidence-Based Precision Oncology with the Cancer Targetome.Characterizing drug-related adverse events by joint analysis of biomedical and genomic data: A case study of drug-induced pulmonary fibrosis.Spontaneous Reporting on Adverse Events by Consumers in the United States: An Analysis of the Food and Drug Administration Adverse Event Reporting System Database.Network-based approach to prediction and population-based validation of in silico drug repurposing.Onset timing of statin-induced musculoskeletal adverse events and concomitant drug-associated shift in onset timing of MAEsSystematic synthesis of a 6-component organic-salt alloy of naftopidil, and pentanary, quaternary and ternary multicomponent crystals
P2860
Q26781811-0EF4E673-88C7-4D2F-B203-E0BA809C8CB6Q26796696-D4A2A802-8892-43F4-AFF4-075FA7EDEDC6Q28543366-E0F60D59-131A-40A2-BF2A-C39B0FE8EA7BQ28543801-A6B56274-421E-4991-BAB1-E68D8A4C4DB0Q28546583-C3109A88-A1F4-4282-A656-2AFE844B85E0Q28969528-AC635203-733E-4E93-BAA7-B6FD35CB80A3Q31097538-25DC37FD-612B-41B3-8B00-E9C0CDD4F33EQ31114073-D1AAF63B-9063-4C86-AD80-FDCA9BCEACFBQ31172137-B0906DCE-1575-432A-B866-FD7B7C9DDE0CQ33767468-F9A334AF-ABC2-41EE-8E8F-C674EDC52AB3Q34767007-0A8DA07E-80BE-47C8-BA67-58E74629B1F0Q35446621-FA63B231-AC47-4F56-AC3B-FF1363BC94DEQ35688664-7412AAE0-0D01-42DB-9AD8-52FD0B45D857Q36087088-FE451379-B6ED-4957-8F21-31DB20FC6950Q36599215-75A2F789-69CE-435E-B2CA-29290F824447Q37149778-BC0D7DB5-DD65-4D98-97BB-1376DE698893Q37733252-6B67A9B3-B649-4926-B87F-899C21AC2E05Q38238962-2D9C44C6-143D-46AB-8B72-189F74888F57Q38503829-2B8C9136-A804-4328-8CBC-DECA6583951CQ38677163-E9FBC930-BA8A-4EA9-8429-ECE20523806BQ38734451-710E96DD-5B96-4C22-9EC7-02B55ECFE53AQ38856202-7ABD7E04-46BA-4F78-A00F-16A291397393Q39173707-973A1190-1FB0-4CE8-A1B9-92E0BAEA0BFEQ40046136-CFCD0C11-E141-490E-A985-8896E47BFEBFQ43536143-3FE5357C-D839-4C94-8B81-26B7EB70F04DQ45791132-367DBA52-E36C-46F9-9BF2-7B7385967D59Q47225742-BE51089F-6185-48BD-A888-07C59FACB5E2Q47893147-EBC1013C-2F2D-46FB-983A-DF8B3FA89D2DQ55009284-007672AF-DD4B-49B8-B277-45A4873B377CQ55433227-9E418215-0AD3-48FE-9961-5AD030AA2A43Q55643995-A56ED316-5930-49D9-BB53-29F07B7F068DQ59133164-B831B269-5572-4825-ABD3-6F6286AD0837Q59133321-465D57D8-8064-483B-B9BC-B9369A144575
P2860
Systems pharmacology of adverse event mitigation by drug combinations
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Systems pharmacology of adverse event mitigation by drug combinations
@en
Systems pharmacology of adverse event mitigation by drug combinations.
@nl
type
label
Systems pharmacology of adverse event mitigation by drug combinations
@en
Systems pharmacology of adverse event mitigation by drug combinations.
@nl
prefLabel
Systems pharmacology of adverse event mitigation by drug combinations
@en
Systems pharmacology of adverse event mitigation by drug combinations.
@nl
P2093
P2860
P1476
Systems pharmacology of adverse event mitigation by drug combinations
@en
P2093
Chiara Giannarelli
Joseph Goldfarb
Juan J Badimon
Ludovic Benard
Mohammad U Zafar
Ravi Iyengar
Roger J Hajjar
Tomohiro Nishimura
Yibang Chen
P2860
P304
P356
10.1126/SCITRANSLMED.3006548
P407
P4510
P577
2013-10-01T00:00:00Z